Kuros Biosciences received FDA 510(k) clearance to market MagnetOs synthetic bone graft putty as an autograft extender in the posterolateral spine. Further, the company has filed for CE Mark approval in the EU.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Per terms of that transaction, the putty clearance triggers a milestone issue of shares to the former owners of Xpand.
Sources: Kuros Biosciences AG; ORTHOWORLD Inc.
Kuros Biosciences received FDA 510(k) clearance to market MagnetOs synthetic bone graft putty as an autograft extender in the posterolateral spine. Further, the company has filed for CE Mark approval in the EU.
MagnetOs was previously cleared in the U.S. in a...
Kuros Biosciences received FDA 510(k) clearance to market MagnetOs synthetic bone graft putty as an autograft extender in the posterolateral spine. Further, the company has filed for CE Mark approval in the EU.
MagnetOs was previously cleared in the U.S. in a granule format under its manufacturer, Xpand Biotechnology, which was acquired by Kuros in 1Q17. Per terms of that transaction, the putty clearance triggers a milestone issue of shares to the former owners of Xpand.
Sources: Kuros Biosciences AG; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
